# OnCo record nct04834024 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04834024/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04834024", "NCT04834024" ;
  schema:name "MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma"@en ;
  schema:description "A phase 3 trial of Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04834024/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04834024> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-06-02" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:companies <https://onco.cc/companies/beijing-mabworks-biotech/> .